Purpose:
A 52 year old woman with a past medical history of Crohn's Disease presented with several months of progressive lethargy, fatigue and one day of bright red blood per rectum. She had lived in Haiti until 1 week prior to admission and she noted that she had been transfused a week before her trip. The patient had been taking 1,000 mg daily of Mesalazine for several years. She appeared comfortable and physical examination reveaeled small petechia on her palate and lower extremities. Her initial WBC count was 3.4×10 9 and hematocrit was 27%. Her platelet count was 1×1069/L. ANC was 550. Absolute reticulocyte count was 0.02×10612/L. ESR was 90 MMS. PT, PTT and INR were normal. The patient was transfused with platelets. EGD, colonoscopy and capsule endoscopy were unremarkable. Serologic tests for Hepatitis, Parvovirus, CMV, EBV, HIV and PNH were negative. Immunofixation showed no clonal spikes. Bone marrow biopsy revealed a hypocellular marrow. A diagnosis of aplastic anemia was made. The patient was given 1 cycle of cyclosporine and ATG (anti thymocyte antiglobulin) and was discharged on prednisone. Her blood work remains consistent with marrow depression. The hematological effects of mesalazine are potentially fatal. Initial pharmacological tests in 4000 patients reported no hematological complications. Since then several reports have associated it with severe hematologic anemias as well, including aplastic anemia, neutropenia and thrombocytopenia. The ages of the patients with aplastic anemia attributed to mesalazine have ranged from 20 to 75 years of age. The dosage and the length of treatment also varied, with one patient experiencing the effect after only 28 days. Patients may present with purpura, bruising, epistaxis or with severe infectious processes precipitated by neutropenia. The exact mechanism of the aplastic anemia is unclear. Mesalazine may induce immunologic suppression of the of hematopoetic stem cells or effect a direct toxic effect upon those cells. The treatment for mesalazine associated aplastic anemia is a combination of ATG, cyclosporine and granulocyte colony -stimulating factor (G-CSF). Conclusion: Aplastic anemia secondary to mesalazine is a rare but recognized phenomenon. Further studies are needed to identify its frequency. Addition to the side effect profile of mesalazine may affect its choice for therapy of patients with inflammatory bowel disease. Purpose: Thromboembolic episodes, either in the form of deep venous thromboembolism (DVT) and/or pulmonary embolism (PE), are infrequently observed in inflammatory bowel disease (IBD). The incidence of venous thromboembolism (VTE) in IBD is 3-3.6 times greater than control groups and is one of the serious complications of IBD, associated with high morbidity and mortality. The underlying mechanisms of increased VTE in IBD are multifactorial and still unclear. The infrequent but serious outcome of such IBD complications demands a challenging diagnosis.
A 61-year-old male with unremarkable past medical history, presented to ED, complaining of dyspnea of one month's duration. On admission, patient was noted to have profound anemia with a Hb 8.0 g/dL, unilateral calf tenderness, significant weight loss and heme positive stool. On system review, he related 3 month history of intermittent diarrhea with blood admixture. Subsequently, Doppler US revealed DVT of the left lower extremity. The extensive pulmonary embolism involving left main pulmonary artery was detected on Spiral chest CT. The patient was transferred to intensive care unit, transfused with packed RBCs and started on low molecular weight heparin (LMWH). After improvement of his anemia, a gastrointestinal work up was undertaken due to strong suspicion of possible malignancy. Colonoscopy showed friable edematous and erythematous mucosa, and shallow scattered ulcerations throughout the large bowel from rectum to cecum. Biopsies revealed moderate to severe active chronic pan-colitis, consistent with ulcerative colitis, without evidence of dysplasia. P-ANCA (anti-neutrophilic cytoplasmic antibodies) was elevated and thrombophila evaluation showed normal homocysteine, protein C, S level, and anti-cardiolipin antibody, but decreased Antithrombin III level. The patient was treated with mesalamine (Asacol) 800 mg po three times a day and mesalamine 4 g retention enema at bedtime. After unremarkable hospital course, the patient was discharged and returned to his country, precluding our follow up. The case illustrates a patient who was admitted to our hospital with massive PE and DVT, and eventually found to have active UC as an underlying etiology. Albeit uncommon, IBD has been established as a specific manifestation and risk factor which shoud be included in the differential diagnosis of VTE.
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Pulmonary Nodules in Ulcerative Colitis
Thanhtam N. Nguyen, BA * , Chris Shepela, MD, Patnaik Mrinal, MD. Gastroenterology, Hepatology and Nutrition & General Internal Medicine, University of Minnesota, Minneapolis, MN. Purpose: Inflammatory bowel disease (IBD) exhibits a wide spectrum of pulmonary manifestations. Pulmonary nodules, however, are infrequently reported in the literature as an extraintestinal manifestation (EIM) of IBD. We report a case of a patient who presented with ulcerative colitis (UC) and multiple pulmonary nodules as an EIM of UC. A 23-yr-old female with a family history of UC was referred to our hospital for acute onset of persistent dry cough and worsening bloody diarrhea. CT of the chest, abdomen, and pelvis revealed multiple bilateral pulmonary nodules, some of which were cavitary in nature, measuring up to 2 cm in diameter and bowel wall thickening involving the entire colon consistent
